La malattia di Anderson-Fabry. Conclusioni

La malattia di Anderson-Fabry. Conclusioni

Abstract non disponibile (aiaf)

Bibliographic Details
Main Authors:	Giovanni Duro, Marco Lombardi
Format:	Article
Language:	Italian
Published:	AboutScience Srl 2017-07-01
Series:	Giornale di Clinica Nefrologia e Dialisi
Subjects:	Fabry disease Lyso-Gb3 alfa-GAL A
Online Access:	https://journals.aboutscience.eu/index.php/gcnd/article/view/708

Similar Items

Biomarkers in Anderson–Fabry Disease
by: Irene Simonetta, et al.
Published: (2020-10-01)

Genotype–Phenotype Correlations in 293 Russian Patients with Causal Fabry Disease Variants
by: Kirill Savostyanov, et al.
Published: (2023-10-01)

The prevalence of Fabry disease among 1009 unrelated patients with hypertrophic cardiomyopathy: a Russian nationwide screening program using NGS technology
by: K. Savostyanov, et al.
Published: (2022-05-01)

Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients
by: Kazuya Tsuboi, et al.
Published: (2017-06-01)

Genetic and phenotypic profile of Fabry disease in the population of Vale do Paraiba and Eastern São Paulo
by: Osvaldo Theodoro da Paz, et al.
Published: (2023-02-01)

Anderson-Fabry: una malattia rara?
by: Paolo Colomba, et al.
Published: (2015-06-01)

Metabolic Fingerprinting of Fabry Disease: Diagnostic and Prognostic Aspects
by: Maria Teresa Rocchetti, et al.
Published: (2022-07-01)

Screening for Fabry Disease in Kidney Transplant Recipients: Experience of a Multidisciplinary Team
by: Massimiliano Veroux, et al.
Published: (2020-10-01)

Late onset variants in Fabry disease: Results in high risk population screenings in Argentina
by: G. Serebrinsky, et al.
Published: (2015-09-01)

Nuovi marcatori
by: Giuseppe Cammarata
Published: (2017-07-01)

Therapeutic challenges in two adolescent male patients with Fabry disease and high antibody titres
by: Aizeddin A. Mhanni, et al.
Published: (2020-09-01)

Aspetti neurologici nella malattia di Anderson-Fabry
by: Antonello Giordano
Published: (2017-08-01)

Nationwide screening of Fabry disease in patients with hypertrophic cardiomyopathy in Czech Republic
by: David Zemánek, et al.
Published: (2022-12-01)

Fabry Disease: Molecular Basis, Pathophysiology, Diagnostics and Potential Therapeutic Directions
by: Ken Kok, et al.
Published: (2021-02-01)

Management of pain in Fabry disease in the UK clinical setting: consensus findings from an expert Delphi panel
by: Karolina M. Stepien, et al.
Published: (2023-07-01)

Lyso-Gb3 Increases αvβ3 Integrin Gene Expression in Cultured Human Podocytes in Fabry Nephropathy
by: Hernán Trimarchi, et al.
Published: (2020-11-01)

Systematic gene therapy derived from an investigative study of AAV2/8 vector gene therapy for Fabry disease
by: Mulan Deng, et al.
Published: (2023-09-01)

Pathologic substrate of gastropathy in Anderson-Fabry disease
by: Alessandro Di Toro, et al.
Published: (2020-06-01)

Aspetti dermatologici nella malattia di Anderson-Fabry
by: Giuseppe Pistone, et al.
Published: (2017-08-01)

A Rapid and Simple UHPLC-MS/MS Method for Quantification of Plasma Globotriaosylsphingosine (lyso-Gb3)
by: Alessandro Perrone, et al.
Published: (2021-12-01)

Newborn Screening for Fabry Disease in Northeastern Italy: Results of Five Years of Experience
by: Vincenza Gragnaniello, et al.
Published: (2021-06-01)

Implementation of Second-Tier Tests in Newborn Screening for Lysosomal Disorders in North Eastern Italy
by: Alberto B. Burlina, et al.
Published: (2019-06-01)

Assessment and impact of dose escalation on anti-drug antibodies in Fabry disease
by: Malte Lenders, et al.
Published: (2022-12-01)

Molecular Pathogenesis of Central and Peripheral Nervous System Complications in Anderson–Fabry Disease
by: Antonino Tuttolomondo, et al.
Published: (2023-12-01)

Endothelial Dysfunction in Fabry Disease Is Related to Glycocalyx Degradation
by: Solvey Pollmann, et al.
Published: (2021-11-01)

RIPK3 Contributes to Lyso-Gb3-Induced Podocyte Death
by: So-Young Kim, et al.
Published: (2021-01-01)

An observational study to investigate the relationship between plasma glucosylsphingosine (lyso-Gb1) concentration and treatment outcomes of patients with Gaucher disease in Japan
by: Hiroyuki Ida, et al.
Published: (2022-11-01)

Association of Shiga toxin glycosphingolipid receptors with membrane microdomains of toxin-sensitive lymphoid and myeloid cells[S]
by: Ivan U. Kouzel, et al.
Published: (2013-03-01)

Ion channels and neuropathic pain
by: Madeleine C Klein, et al.
Published: (2018-11-01)

CARS Imaging Advances Early Diagnosis of Cardiac Manifestation of Fabry Disease
by: Elen Tolstik, et al.
Published: (2022-05-01)

Il DBS come test diagnostico nella malattia di Fabry
by: Simone Scalia
Published: (2017-07-01)

Evaluating enzyme replacement therapies for Anderson-Fabry disease: commentary on a recent report
by: Roberto Giugliani, et al.
Published: (2018-10-01)

Epidemiology of Fabry disease in patients in hemodialysis in the Madrid community
by: Elena Corchete Prats, et al.
Published: (2023-07-01)

Epidemiology of Fabry disease in patients in hemodialysis in the Madrid community
by: Elena Corchete Prats, et al.
Published: (2023-07-01)

Il coinvolgimento cardiaco nella malattia di Fabry
by: Maurizio Pieroni
Published: (2017-09-01)

Multidisciplinary Management of Fabry Disease: Current Perspectives
by: Paim-Marques L, et al.
Published: (2022-03-01)

Prevalence of Fabry disease in dialysis patients: Western Australia Fabry disease screening study - the FoRWARD study
by: Sadia Jahan, et al.
Published: (2020-01-01)

Morphological Hallmarks of Classical Fabry Disease: An Ultrastructural Study in a Large Spanish Family
by: Beatriz San Millán-Tejado, et al.
Published: (2023-08-01)

La malattia di Fabry: una sindrome cardio-renale da malattia sistemica
by: Fulvio Floccari, et al.
Published: (2013-11-01)

Using Liquid Chromatography-Tandem Mass Spectrometry in Detecting Plasma Lyso-GL3 Levels in Patients with Fabry Disease and the Association Analysis of Phenotype-Genotype of the Disease
by: OUYANG Yan, et al.
Published: (2024-01-01)